Printer Friendly

FOUNTAIN PHARMACEUTICALS SIGNS AGREEMENT WITH BROCADES PHARMA

 FOUNTAIN PHARMACEUTICALS SIGNS AGREEMENT WITH BROCADES PHARMA
 LARGO, Fla., March 12 /PRNewswire/ -- Fountain Pharmaceuticals, Inc. (NASDAQ: FPHI), Largo, announced today it has entered into agreements with Brocades Pharma bv, the European organization of Yamanouchi Pharmaceutical Co. Ltd.
 Under one of the agreements, Brocades Pharma will commence European marketing and distribution of Fountain's DAYLONG(TM) Lyphazome(TM) water-based sunscreen product line. This line includes SPF8 and SPF20 products which are waterproof and provide sunscreen protection for at least eight hours. The initial European market introduction is scheduled for later this year.
 An additional agreement calls for Fountain Pharmaceuticals, Inc. to apply its technology to several compounds selected by Brocades Pharma for potential utilization in the treatment and management of various dermatological diseases. Research is scheduled to commence within the first quarter of 1992.
 Brocades Pharma is the European member of the Yamanouchi Group, a world leader in the manufacturing of pharmaceutical and fine chemical products.
 A spokesperson for Fountain stated that although it is too premature to determine the level of sales that may be generated by these arrangements, the company is extremely pleased at the opportunity of working with Brocades and excited at the prospects of opening marketing and distribution channels in the European marketplace.
 Fountain Pharmaceuticals, Inc. is a development stage company specializing in the application of encapsulated drug delivery systems that improve drug compound delivery and enhance effectiveness of existing products. Fountain also develops proprietary products with applications in agricultural and consumer goods industries.
 -0- 3/12/92
 /CONTACT: Clark A. Marcus of Fountain Pharmaceuticals, Inc. 813-392-5300/
 (FPHI) CO: Fountain Pharmaceuticals, Inc.; Brocades Pharma bv;
 Yamanouchi Pharmaceutical Co. Ltd. ST: Florida IN: MTC SU:


MK-JS -- PH022 -- 7513 03/12/92 15:59 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 12, 1992
Words:285
Previous Article:UNITED THERMAL REPORTS RESULTS
Next Article:AT&T ANNOUNCES NEW AT&T CUSTOM CALLING CARD
Topics:


Related Articles
LIDAK PHARMACEUTICALS AND BROCADES PHARMA ANNOUNCE LICENSE AGREEMENT
THE WEST COMPANY, DAIKYO GOMU SEIKO LTD. AND PHARMA-GUMMI WIMMER WEST GMBH SIGN INTERNATIONAL AGREEMENT
PAIN CONTROL: BIOCHEM AND ASTRA AGREEMENT SIGNED TODAY
FOUNTAIN PHARMACEUTICALS ENTERS LICENSING AGREEMENT WITH SPIRIG A.G.
LIDAK SIGNS LICENSING AGREEMENT WITH CTS CHEMICAL INDUSTRIES FOR MANUFACTURE AND MARKETING OF LIDAKOL
NYCOMED BECOMES NEW ASSOCIATE FOR FOUNTAIN PHARMACEUTICALS IN EUROPE
MGI PHARMA FINALIZES LICENSING AGREEMENT WITH KISSEI PHARMACEUTICAL CO., LTD FOR SALAGEN(R) TABLETS IN JAPAN
DUPONT MERCK PHARMA FACILITY IN MANATI TO MANUFACTURE PRODUCTS FOR ARES-SERONO
FOUNTAIN EXPANSION VIA EUROPEAN LICENSEES
ORION PHARMA GRANTS BROAD MARKETING RIGHTS OF PARKINSON'S DISEASE DRUG TO SANDOZ PHARMA LTD.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters